Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Tomorrow Sell Off of Epic Proportions SELL SELL

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
MARINO Member Profile
 
Followed By 148
Posts 15,397
Boards Moderated 0
Alias Born 10/25/06
160x600 placeholder
Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 6:07:01 AM
Amarin EPS beats by $0.04, beats on revenue Seeking Alpha - 2/25/2021 5:58:27 AM
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 2/25/2021 5:55:00 AM
Amarin Q4 2020 Earnings Preview Seeking Alpha - 2/24/2021 11:55:46 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 2/18/2021 6:05:00 AM
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021 GlobeNewswire Inc. - 2/17/2021 8:05:00 AM
Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. InvestorsHub NewsWire - 2/12/2021 6:26:34 AM
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong GlobeNewswire Inc. - 2/9/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/29/2021 5:01:28 PM
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction GlobeNewswire Inc. - 1/29/2021 12:51:51 PM
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Re... PR Newswire (Canada) - 1/28/2021 6:30:00 AM
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider GlobeNewswire Inc. - 1/25/2021 7:35:00 PM
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascul... GlobeNewswire Inc. - 1/21/2021 4:30:00 PM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2021 6:16:40 AM
Amarin Provides Preliminary 2020 Results and 2021 Outlook GlobeNewswire Inc. - 1/7/2021 6:05:00 AM
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/4/2021 6:05:00 AM
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (N... GlobeNewswire Inc. - 12/14/2020 5:00:00 AM
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA®... GlobeNewswire Inc. - 12/12/2020 9:30:00 PM
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessio... GlobeNewswire Inc. - 12/7/2020 7:00:00 AM
Amarin Files Patent Infringement Lawsuit Against Hikma GlobeNewswire Inc. - 11/30/2020 7:54:44 PM
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) GlobeNewswire Inc. - 11/24/2020 6:05:00 AM
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China GlobeNewswire Inc. - 11/19/2020 6:30:00 PM
MARINO   Monday, 10/01/18 09:57:44 PM
Re: None
Post # of 327571 
Tomorrow Sell Off of Epic Proportions
SELL SELL

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences